NASDAQ:ENTO Entero Therapeutics (ENTO) Stock Price, News & Analysis $3.86 -0.03 (-0.77%) As of 09/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Entero Therapeutics Stock (NASDAQ:ENTO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entero Therapeutics alerts:Sign Up Key Stats Today's Range$3.77▼$4.1250-Day Range$2.60▼$4.1752-Week Range$0.32▼$5.84Volume30,449 shsAverage Volume2.80 million shsMarket Capitalization$6.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Entero Therapeutics, Inc. (NASDAQ:ENTO) is a clinical-stage biopharmaceutical company focused on developing orally delivered therapies for gastrointestinal diseases. The company’s research and development programs are designed to address conditions involving impaired digestion, intestinal inflammation and other disorders for which targeted oral treatments may offer clinical benefits. Entero’s lead program is adrulipase, an investigational oral recombinant enzyme intended to replace pancreatic lipase in people with exocrine pancreatic insufficiency, including patients with conditions such as chronic pancreatitis or cystic fibrosis. The company has also developed formulations of niclosamide, an established compound being investigated for potential use in inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease. The company was formerly known as First Wave BioPharma, Inc. and adopted the Entero Therapeutics name as part of its strategic focus on gastrointestinal therapeutics. Its product candidates remain subject to clinical development and regulatory review, and the company’s programs and indications may change as research progresses.AI Generated. May Contain Errors. Read More Entero Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreENTO MarketRank™: Entero Therapeutics scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingEntero Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEntero Therapeutics has received no research coverage in the past 90 days.Read more about Entero Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Entero Therapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entero Therapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ENTO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntero Therapeutics does not currently pay a dividend.Dividend GrowthEntero Therapeutics does not have a long track record of dividend growth. News and Social Media1.7 / 5News SentimentN/A News SentimentEntero Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Technology companies. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Entero Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.75% of the stock of Entero Therapeutics is held by insiders.Percentage Held by Institutions12.30% of the stock of Entero Therapeutics is held by institutions.Read more about Entero Therapeutics' insider trading history. Receive ENTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENTO Stock News HeadlinesEntero Therapeutics (NASDAQ:ENTO) Shares Down 2.6% - What's Next?September 18, 2026 | americanbankingnews.comGridAI Technologies Faces Default on Revolving Loan AgreementApril 24, 2026 | tipranks.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.September 25 at 1:00 AM | Altimetry (Ad)Entero Therapeutics Inc.December 4, 2025 | wsj.comNASDAQ: ENTO’s Grid AI Strikes Texas Hyperscale Deal as its $50M Industrial Software Platform Enters the AI RaceNovember 19, 2025 | msn.comEntero's Grid AI Announces Major U.S. Expansion and Incoming Leadership to Accelerate AI Infrastructure StrategyNovember 19, 2025 | finance.yahoo.comEntero Therapeutics Delays Q3 10-Q FilingNovember 17, 2025 | tipranks.comEntero’s Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure StrategyNovember 16, 2025 | usatoday.comSee More Headlines ENTO Stock Analysis - Frequently Asked Questions How have ENTO shares performed this year? Entero Therapeutics' stock was trading at $4.66 at the start of the year. Since then, ENTO stock has decreased by 17.2% and is now trading at $3.86. How were Entero Therapeutics' earnings last quarter? Entero Therapeutics, Inc. (NASDAQ:ENTO) issued its quarterly earnings results on Thursday, August, 14th. The company reported ($0.42) EPS for the quarter. When did Entero Therapeutics' stock split? Entero Therapeutics's stock reverse split on Monday, August 18th 2025.A 1-3 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, August 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. When did Entero Therapeutics IPO? Entero Therapeutics (ENTO) raised $5 million in an initial public offering (IPO) on Friday, September 16th 2016. The company issued 960,000 shares at $5.50 per share. Who are Entero Therapeutics' major shareholders? Top institutional investors of Entero Therapeutics include ADAR1 Capital Management LLC (132.56%), Seven Fleet Capital Management LP (25.89%), Elmind Capital LP (13.22%) and Persistent Asset Partners Ltd (7.21%). Insiders that own company stock include James Sapirstein and Sarah Romano. View institutional ownership trends. How do I buy shares of Entero Therapeutics? Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include CDT Equity (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Dare Bioscience (DARE), PMGC (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST). Company Calendar Last Earnings8/14/2025Today9/25/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorTechnology Industry Software Sub-IndustryApplication Software Current SymbolNASDAQ:ENTO Previous SymbolNASDAQ:ENTO CIK1604191 Webwww.enterothera.com Phone561-589-7020FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-461.02% Return on Assets-14.72% Debt Debt-to-Equity RatioN/A Current Ratio2.62 Quick Ratio2.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($2.45) per share Price / Book-1.58Miscellaneous Outstanding Shares1,588,000Free Float3,337,000Market Cap$6.13 million OptionableN/A Beta1.19 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ENTO) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
